Literature DB >> 20223637

Epigenetics and SLE: RFX1 downregulation causes CD11a and CD70 overexpression by altering epigenetic modifications in lupus CD4+ T cells.

Ming Zhao1, Yimin Sun, Fei Gao, Xiaoyan Wu, Jinling Tang, Heng Yin, Yongqi Luo, Bruce Richardson, Qianjin Lu.   

Abstract

DNA demethylation and histone hyperacetylation of CD11a and CD70 regulatory regions contribute to the development of autoreactivity and autoantibody overstimulation in CD4(+) T cells of patients with systemic lupus erythematosus (SLE). However, the mechanisms causing these changes remain largely unknown. We report that the expression and activity of the transcription factor RFX1 are decreased in SLE CD4(+) T cells. We demonstrate that RFX1 affects DNA methylation and histone acetylation in CD4(+) T cells by recruiting the co-repressors DNMT1 and HDAC1 to the CD11a and CD70 promoters, and thereby represses their expression. Reducing RFX1 in CD4(+) T cells is sufficient to cause lupus-like T and B cell hyperactivity, whereas overexpressing RFX1 suppresses T cell reactivity. These findings reveal a crucial role for RFX1 in regulating the epigenetic status of T cells, and demonstrate that autoimmune responses in SLE are due in part to RFX1 downregulation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20223637     DOI: 10.1016/j.jaut.2010.02.002

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  59 in total

Review 1.  The therapeutic potential of epigenetics in autoimmune diseases.

Authors:  Maria De Santis; Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2012-02       Impact factor: 8.667

Review 2.  The epigenetics of autoimmunity.

Authors:  Francesca Meda; Marco Folci; Andrea Baccarelli; Carlo Selmi
Journal:  Cell Mol Immunol       Date:  2011-01-31       Impact factor: 11.530

3.  CREMα suppresses spleen tyrosine kinase expression in normal but not systemic lupus erythematosus T cells.

Authors:  Debjani Ghosh; Katalin Kis-Toth; Yuang-Taung Juang; George C Tsokos
Journal:  Arthritis Rheum       Date:  2012-03

Review 4.  Targeting lymphocyte signaling pathways as a therapeutic approach to systemic lupus erythematosus.

Authors:  Vasileios C Kyttaris; George C Tsokos
Journal:  Curr Opin Rheumatol       Date:  2011-09       Impact factor: 5.006

5.  DUSP23 is over-expressed and linked to the expression of DNMTs in CD4+ T cells from systemic lupus erythematosus patients.

Authors:  E Balada; L Felip; J Ordi-Ros; M Vilardell-Tarrés
Journal:  Clin Exp Immunol       Date:  2016-11-16       Impact factor: 4.330

Review 6.  The long-term marriage between autoimmunity and internal medicine: a homage to Manuel Carlos Dias.

Authors:  Carlo Selmi; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2012-12       Impact factor: 8.667

Review 7.  Prohibitin: A hypothetical target for sex-based new therapeutics for metabolic and immune diseases.

Authors:  Suresh Mishra; Bl Grégoire Nyomba
Journal:  Exp Biol Med (Maywood)       Date:  2019-02-04

Review 8.  DNA methylation alterations in the pathogenesis of lupus.

Authors:  S H Chen; Q L Lv; L Hu; M J Peng; G H Wang; B Sun
Journal:  Clin Exp Immunol       Date:  2016-11-01       Impact factor: 4.330

Review 9.  cAMP responsive element modulator: a critical regulator of cytokine production.

Authors:  Thomas Rauen; Christian M Hedrich; Klaus Tenbrock; George C Tsokos
Journal:  Trends Mol Med       Date:  2013-03-13       Impact factor: 11.951

10.  Hypomethylation of IL10 and IL13 promoters in CD4+ T cells of patients with systemic lupus erythematosus.

Authors:  Ming Zhao; Jinling Tang; Fei Gao; Xiaoyan Wu; Yunsheng Liang; Heng Yin; Qianjin Lu
Journal:  J Biomed Biotechnol       Date:  2010-06-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.